首页> 外文期刊>Bone marrow transplantation >Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.
【24h】

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.

机译:肾癌和结肠癌患者的低强度调理和造血干细胞移植。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We have evaluated whether allogeneic hematopoietic stem cell transplantation (HSCT) could induce an antitumor effect in patients with metastatic solid tumors. A total of 12 HLA-identical siblings and 6 HLA-A-, -B- and -DRbeta1-compatible unrelated grafts were used. Diagnoses were adenocarcinoma of kidney (n=10), colon (n=6), breast (n=1) and cholangiocarcinoma (n=1). Conditioning was fludarabine 30 mg/m(2)/day for 3 days and 2 Gy of total body irradiation. Recipients of unrelated HSCT were also given thymoglobuline and two additional days of fludarabine. The median CD34+ cell dose was 7.5x10(6)/kg. Immunosuppression was mycophenolate mofetil and cyclosporin. Among all, 12 patients became complete donor chimeras within a median of 28, 29 and 65 days for B, myeloid and T cells, respectively. Two patients rejected the grafts, one developed marrow aplasia and three were mixed chimeras. The probability of grades II-IV acute graft-versus-host-disease (GVHD) was 57%. Regression of all tumor metastases was seen in one patient with colon carcinoma. Another patient with colon and two with renal carcinoma had regression of lung metastases, but progression of metastases in the liver and/or bone. Necrosis of lung metastasis was found in one further patient with renal carcinoma who died of graft-versus-host-disease (GVHD). In all, 10 patients died; four of transplant-related complications, one of trauma and five of progressive disease. Thus, progression was common after allogeneic HSCT in unselected patients with advanced solid tumors. However, the regression of some metastases associated with GVHD provides suggestive evidence that the GVHD effect may occur in renal and colon adenocarcinoma using reduced intensity conditioning.Bone Marrow Transplantation (2003) 31, 253-261. doi:10.1038/sj.bmt.1703811
机译:我们评估了同种异体造血干细胞移植(HSCT)是否可以在转移性实体瘤患者中诱导抗肿瘤作用。总共使用了12个HLA相同的兄弟姐妹和6个HLA-A-,-B-和-DRbeta1兼容的不相关移植物。诊断为肾腺癌(n = 10),结肠腺癌(n = 6),乳腺癌(n = 1)和胆管癌(n = 1)。条件是氟达拉滨30 mg / m(2)/天,持续3天,全身辐射2 Gy。不相关的HSCT的接受者也接受了胸腺胆碱和另外两天的氟达拉滨治疗。中值CD34 +细胞剂量为7.5x10(6)/ kg。免疫抑制为霉酚酸酯和环孢菌素。其中,有12位患者分别在B,髓样和T细胞的中位数28、29和65天内成为完全的供体嵌合体。两名患者拒绝移植,一名发生骨髓发育不全,三名混合嵌合体。 II-IV级急性移植物抗宿主病(GVHD)的可能性为57%。一名结肠癌患者发现所有肿瘤转移均消退。另一名结肠癌患者和两名肾癌患者肺转移消退,但肝和/或骨转移进展。在另一位死于移植物抗宿主病(GVHD)的肾癌患者中发现肺转移坏死。共有10例患者死亡。其中有四项与移植相关的并发症,其中一项为创伤,另一项为五种进行性疾病。因此,在未选择的晚期实体瘤患者中,同种异体造血干细胞移植后进展很常见。然而,与GVHD相关的一些转移的消退提供了暗示性的证据,表明使用降低的强度调节在肾和结肠腺癌中可能发生GV​​HD作用。骨髓移植(2003)31,253-261。 doi:10.1038 / sj.bmt.1703811

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号